Global Leukemia Therapeutics Market – By Disease Type (Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, and Acute Myeloid Leukemia), By Drug Class (Small Molecules and Biologics), and By Regions (North America, Europe, Asia Pacific, and Rest of the World): Forecast up to 2025
- January, 2020
- Domain: Healthcare - Pharmaceuticals
- Get Free 10% Customization in this Report
This market research report includes a detailed segmentation of the global leukemia therapeutics market by disease type (chronic myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, and acute myeloid leukemia), by drug class (small molecule and biologics), and by regions (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Leukemia Therapeutics Market Research:
Infoholic’s market research report predicts that the global leukemia therapeutics market will grow at a CAGR of 6.2% during the forecast period 2019–2025. Leukemia refers to the group of blood cancer that usually develops in the bone marrow, resulting in the formation of abnormal blood cells. Leukemia is subdivided into lymphoblastic or lymphocytic leukemias and myeloid or myelogenous leukemias that include acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).
The upsurge in the incidence of leukemia cases across the globe, rising elderly population, and the advent of innovative therapies are among the factors driving the market growth. In the US, an estimated 61,780 people were expected to be diagnosed with leukemia in 2019. Approximately 10,670 people died of AML in 2018. In Europe, nearly 30,000 people had CLL in 2018. Leukemia was the 8th most commonly diagnosed cancer in Australia with 3,905 cases in 2015 and it is estimated that leukemia will remain the 8th most commonly diagnosed cancer in 2019. However, strict regulatory guidelines, increased cost of the drug, and side effects associated with drugs are few of the factors that may prove detrimental to the market. Growing investment in R&D for the development of the new drugs, promising pipeline, and opportunities in emerging economies are anticipated to enhance the revenue of the leukemia therapeutics market in the next five years.
The industry generates the majority of the revenue from the key players operating in this field; few of them include Novartis AG, F-Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi S.A., Bristol–Myers Squibb Company, and AbbVie Inc. According to the Infoholic Research analysis, North America accounted for the largest share of the global leukemia therapeutics market in 2018 and will retain a high position during the forecast period. North America is followed by Europe with a share of more than 25% of the global market in 2018.
By Disease Type:
- Chronic Myeloid Leukemia (CML)
- Chronic Lymphocytic Leukemia (CLL)
- Acute Lymphocytic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
In 2018, the chronic myeloid leukemia segment accounted for the largest share and is expected to grow at a mid-single-digit CAGR by 2025. The high prevalence rate of CML and the availability of a huge number of treatment choices make the segment the largest shareholder in the global leukemia therapeutics market.
By Molecule Type:
- Small Molecules
Based on the molecule type analysis, the small molecules segment dominated the market in 2018 with a share of over 75% and is expected to maintain this position throughout the forecast period. Biologics is expected to grow at a high CAGR during the forecast period 2019–2025.
- North America
- Asia Pacific
- Rest of the World
Based on geography, North America dominated the market in 2018 with a share of over 40% and is expected to grow at mid-single-digit CAGR during the forecast period 2019–2025. The high incidence and prevalence rate of the disease, increasing awareness on personalized medicine, and the existence of reputed players extensively involved in the commercialization of branded therapeutics make the region a dominant shareholder in the global leukemia therapeutics market. Asia Pacific is projected to grow at a high CAGR during the forecast period 2019–2025.
Global Leukemia Therapeutics Market Research Competitive Analysis: The market is growing at a steady rate with a CAGR of 6.2% during the forecast period 2019–2025. There are many new drug launches, approval, development, and funding related to leukemia drugs owing to the increased patient base across the globe. For instance, in 2019, Ivosidenib (TIBSOVO) developed by Agios Pharmaceuticals, Inc. was approved by the FDA for the treatment of AML in older patients with a susceptible IDH1 mutation who have comorbidities that preclude the use of intensive induction chemotherapy. Astellas Pharma received FDA approval for gilteritinib, in November 2018, the first-ever inhibitor drug explicitly approved for treating patients with relapsed or refractory AML with a mutation in the FLT3 gene. FDA granted a supplemental approval to acalabrutinib (Calquence) developed by AstraZeneca to treat CLL or SLL in December 2019.
There is an increasing collaboration to develop novel leukemia therapeutics. For instance, MD Anderson Cancer Center and Ascentage Pharma entered into a five-year collaboration that aims to accelerate clinical development of novel apoptosis-targeted and tyrosine kinase inhibitor drug candidates for leukemia treatment.
- Novartis AG
- F-Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Sanofi S.A.
- Bristol–Myers Squibb Company
- AbbVie Inc.
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- Gilead Science Inc.
- Eisai Co. Ltd.
- Biogen Inc.
Key Competitive Facts:
- The pipeline of oncology drugs in the clinical development has expanded by 45% over the past 10 years; 87% of the late-stage pipeline is targeted therapies, which include small molecule protein kinase inhibitors and biologic monoclonal antibodies.
- Jazz Pharmaceuticals plc received European Commission approval for its marketing authorization application for Vyxeos in August 2018 for the treatment of newly diagnosed AML with myelodysplasia-related changes in adult patients or therapy-related acute myeloid leukemia.
Benefits – The report provides complete details about the sub-segment of the global leukemia therapeutics market. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the pharmaceutical segment in the upcoming years, along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
- Understanding the potential market opportunity with precise market size and forecast data.
- Detailed market analysis focusing on the growth of the leukemia therapeutics industry.
- Factors influencing the growth of the leukemia therapeutics market.
- In-depth competitive analysis of dominant and pure-play vendors.
- Prediction analysis of the leukemia therapeutics industry in both developed and developing regions.
- Key insights related to major segments of the leukemia therapeutics market.
- Latest market trend analysis impacting the buying behavior of the consumers.
1 Industry Outlook
1.1 Industry Overview
1.1.2 Global Driver for Pharmaceutical Demand
1.1.3 R&D Pipeline in the Pharmaceutical Industry
1.2 Industry Trends
1.3 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.3 Trends in the Leukemia Therapeutics Market
3.4 Related Markets
3.4.1 Lung Cancer Drugs
3.4.2 Over the Counter (OTC) Drugs
3.4.3 Respiratory Drugs
3.4.4 Breast Cancer Drugs
4 Market Outlook
4.1 Market Segmentation
4.2 PEST Analysis
4.3 Porter 5 (Five) Forces
5 Market Characteristics
5.1 DRO –Market Dynamics
220.127.116.11 Increasing incidence of leukemia cases across the globe
18.104.22.168 Rising elderly population
22.214.171.124 Promising pipeline of leukemia drugs
126.96.36.199 Opportunities in emerging economies
188.8.131.52 High cost of the drugs
184.108.40.206 Strict regulatory guidelines
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Disease Type: Market Size and Analysis
6.2 Acute Myeloid Leukemia (AML)
6.3 Acute Lymphocytic Leukemia (ALL)
6.4 Chronic Lymphocytic Leukemia (CLL)
6.5 Chronic Myeloid Leukemia (CML)
7 Molecule Type: Market Size and Analysis
7.3 Small Molecules
8 Regions: Market Size and Analysis
8.2 North America
8.4 Asia Pacific
8.5 Rest of the World
9 Competitive Landscape
10 Vendor Profile
10.1 Novartis AG
10.2 F. Hoffmann-La Roche Ltd.
10.3 Sanofi S.A.
10.4 Bristol–Myers Squibb Company
10.5 Pfizer Inc.
10.6 AbbVie Inc.
11 Companies to Watch For
11.1 Amgen Inc.
11.2 Gilead Science Inc.
11.3 Takeda Pharmaceutical Company Limited
11.5 Eisai Co. Ltd.
11.6 Biogen Inc.
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
Market related information is congregated from both primary and secondary sources.
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.